LucyTx-1212

LucyTx-1212 is a **proprietary small molecule drug candidate** developed by Lucy Therapeutics for the treatment of neurological diseases, primarily Parkinson’s disease. The compound is designed to **selectively inhibit the mitochondrial protein complex F1F0-ATPase**, a key component of the electron transport chain (ETC) crucial for cellular energy (ATP) production. By blocking F1F0-ATPase, LucyTx-1212 aims to rescue mitochondrial function, reduce neuronal death, and decrease levels of alpha-synuclein, a pathogenic protein implicated in Parkinson’s disease. Preclinical studies demonstrated that LucyTx-1212 can restore neuronal health and function without significant safety issues in laboratory and rodent models. The company is also investigating this drug candidate for other neurological diseases, including Alzheimer’s disease and Rett syndrome, as part of its platform focusing on the mitochondrial roots of complex neurological disorders[1][3][5][7].